[go: up one dir, main page]

EA201600486A1 - PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE - Google Patents

PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE

Info

Publication number
EA201600486A1
EA201600486A1 EA201600486A EA201600486A EA201600486A1 EA 201600486 A1 EA201600486 A1 EA 201600486A1 EA 201600486 A EA201600486 A EA 201600486A EA 201600486 A EA201600486 A EA 201600486A EA 201600486 A1 EA201600486 A1 EA 201600486A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
methylbenzamide
methyl
pharmaceutical compositions
ethanimidoil
Prior art date
Application number
EA201600486A
Other languages
Russian (ru)
Other versions
EA030138B1 (en
Inventor
Дмитрий Геннадьевич ТОВБИН
Дмитрий Николаевич ТАРАСОВ
Дмитрий Викторович МАЛАХОВ
Original Assignee
Общество С Ограниченной Ответственностью "Фармадиол"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фармадиол" filed Critical Общество С Ограниченной Ответственностью "Фармадиол"
Priority to EA201600486A priority Critical patent/EA030138B1/en
Priority to PCT/RU2017/050049 priority patent/WO2017217895A1/en
Publication of EA201600486A1 publication Critical patent/EA201600486A1/en
Publication of EA030138B1 publication Critical patent/EA030138B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины, в частности к фармакологии, а именно к новым фармацевтическим композициям для перорального применения при лечении заболеваний, связанных с повышенным тромбообразованием. Композиции содержат антикоагулянт N-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид или его фармацевтически приемлемую соль, являющийся ингибитором фактора Ха, и полипренол, и защищены кишечно-растворимой оболочкой или капсулой от разрушения желудочным соком. Композиции обладают высокой эффективностью и биодоступностью и могут быть использованы для лечения и профилактики состояний, характеризующихся нежелательным тромбозом.The invention relates to the field of medicine, in particular to pharmacology, namely to new pharmaceutical compositions for oral administration in the treatment of diseases associated with increased thrombosis. The compositions contain the anticoagulant N- (5-chloropyridin-2-yl) -2 - ({4- [ethanimidoyl (methyl) amino] benzoyl} amino) -5-methylbenzamide or its pharmaceutically acceptable salt, an inhibitor of factor Xa, and polyprenol, and protected by enteric-soluble shell or capsule from destruction by gastric juice. The compositions are highly effective and bioavailable and can be used for the treatment and prevention of conditions characterized by undesirable thrombosis.

EA201600486A 2016-06-15 2016-06-15 Pharmaceutical compositions comprising an anticoagulant n-(5-chloropyridin-2-yl)-2-({4-[ethane imidoyl(methyl)amino]benzoyl}amino)-5-methyl benzamide EA030138B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201600486A EA030138B1 (en) 2016-06-15 2016-06-15 Pharmaceutical compositions comprising an anticoagulant n-(5-chloropyridin-2-yl)-2-({4-[ethane imidoyl(methyl)amino]benzoyl}amino)-5-methyl benzamide
PCT/RU2017/050049 WO2017217895A1 (en) 2016-06-15 2017-06-13 Pharmaceutical compositions comprising anticoagulant n-(5-chloropyridine-2-yl)-2-({4-[ethanimidoil(methyl)amino]benzoyl}amino)-5-methylbenzamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201600486A EA030138B1 (en) 2016-06-15 2016-06-15 Pharmaceutical compositions comprising an anticoagulant n-(5-chloropyridin-2-yl)-2-({4-[ethane imidoyl(methyl)amino]benzoyl}amino)-5-methyl benzamide

Publications (2)

Publication Number Publication Date
EA201600486A1 true EA201600486A1 (en) 2017-12-29
EA030138B1 EA030138B1 (en) 2018-06-29

Family

ID=60664137

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600486A EA030138B1 (en) 2016-06-15 2016-06-15 Pharmaceutical compositions comprising an anticoagulant n-(5-chloropyridin-2-yl)-2-({4-[ethane imidoyl(methyl)amino]benzoyl}amino)-5-methyl benzamide

Country Status (2)

Country Link
EA (1) EA030138B1 (en)
WO (1) WO2017217895A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2698202C2 (en) * 2016-06-01 2019-08-23 Закрытое акционерное общество "ФАРМА ВАМ" METHOD FOR PRODUCING DIRECT FACTOR Xa INHIBITOR
EA201800084A1 (en) * 2018-01-19 2019-07-31 Общество С Ограниченной Ответственностью "Фармадиол" NEW AMIDINE INHIBITORS FACTOR Ha
RU2702127C1 (en) * 2018-11-28 2019-10-04 Вагиф Султанович Султанов Medicinal agent, a pharmaceutical composition, an active ingredient of the pharmaceutical composition and a method of treating cognitive disorders in the patients suffering acute myocardial infarction
CN114685448B (en) * 2020-12-25 2025-01-07 江苏天士力帝益药业有限公司 A method for synthesizing zopiclone impurity pyrazine-2-carboxylic acid (5-chloro-pyridin-2-yl)-amide
WO2022211680A1 (en) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Process for producing the anticoagulant n-(5-chloropyridin-2-yl)-2-({4-[ethanimidoyl(methyl)amino]benzoyl}amino)-5-methylbenzamide hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5791932A (en) * 1980-11-28 1982-06-08 Kuraray Co Ltd Polyprenyl compound
BRPI0908114A2 (en) * 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd controlled release oral tablet
EA015918B1 (en) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН URETHANES, UREAS, AMIDES AND RELATED INHIBITORS OF Xa FACTORS
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
RU2554735C1 (en) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Pharmaceutical composition containing rabeprazole and method for producing it

Also Published As

Publication number Publication date
WO2017217895A1 (en) 2017-12-21
EA030138B1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
CY1123260T1 (en) A SODIUM SALT OF N-((1,2,3,5,6,7-EXAXPO-S-INDAKEN-4-YL)CARBAMOYL)-1-ISOPROPYL-1H-PYRAZOLE-3-SULFONAMIDE
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
EA202190960A1 (en) CONDENSED PYRROLINES THAT ACT AS INHIBITORS OF UBIKVITIN SPECIFIC PROTEASE 30 (USP30)
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
EA201600486A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
CY1122792T1 (en) MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
EA201890654A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS
EA201490495A1 (en) NEW EASY DESTROYING ROCK INHIBITORS
EA201590847A1 (en) NEW ROCK INHIBITORS
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA202190586A1 (en) N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXIPICOLINAMIDES ACCEPTED AS CCR6 INHIBITORS
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA202191239A1 (en) COMPOUNDS AND THEIR APPLICATION FOR TREATMENT OF 1-ANTITRIPSIN DEFICIENCY
EA202190429A1 (en) Bioavailable oral dosage forms
EA202190621A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTITLAMBOCYTIC AND GASTRIC ACID SECRETION INHIBITOR
MA43876B1 (en) Pharmaceutical compositions and their uses against lysosomal storage diseases
EA201792237A1 (en) PHARMACEUTICAL COMPOSITIONS
EA202190510A1 (en) A NEW DRUG FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASE
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
EA201792265A1 (en) METHODS OF TREATING CARDIOVASCULAR DISEASES
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY